0000947871-20-000145.txt : 20200225 0000947871-20-000145.hdr.sgml : 20200225 20200225171154 ACCESSION NUMBER: 0000947871-20-000145 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200114 FILED AS OF DATE: 20200225 DATE AS OF CHANGE: 20200225 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chimovits Erez CENTRAL INDEX KEY: 0001706399 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36620 FILM NUMBER: 20652024 MAIL ADDRESS: STREET 1: P.O. BOX 4023 CITY: HERZLIYA PITUACH STATE: L3 ZIP: 4614001 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Novus Therapeutics, Inc. CENTRAL INDEX KEY: 0001404281 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 19900 MACARTHUR BLVD. STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: 949-238-8090 MAIL ADDRESS: STREET 1: 19900 MACARTHUR BLVD. STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 FORMER COMPANY: FORMER CONFORMED NAME: Tokai Pharmaceuticals Inc DATE OF NAME CHANGE: 20070622 4 1 ownership.xml X0306 4 2020-01-14 0 0001404281 Novus Therapeutics, Inc. NVUS 0001706399 Chimovits Erez C/O NOVUS THERAPEUTICS, INC. 19900 MACARTHUR BLVD, SUITE 550 IRVINE CA 92612 1 0 1 0 Warrants to Purchase Common Stock 2020-01-14 4 S 0 646204 0.20 A 2019-05-02 2020-11-02 Common Stock 646204 0 I See Footnotes Warrants to Purchase Common Stock 2020-01-14 4 S 0 646204 0.20 A 2019-05-02 2024-05-02 Common Stock 646204 0 I See Footnotes The Reporting Person is the designated representative of OrbiMed Israel GP Ltd. on the Issuer's Board of Directors. The reportable securities are owned directly by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel") is the general partner of OrbiMed BioFund. The Reporting Person disclaims beneficial ownership of the securities reported herein for the purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. Warrants ("Warrants") to purchase shares of the Issuer's common stock ("Shares"). The Warrants are immediately exercisable and have an exercise price of $4.00 per Share. /s/ Erez Chimovits 2020-02-25